DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes

Information source: EMS
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: GENITAL HERPES

Intervention: Famciclovir (Drug); Aciclovir (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: EMS

Official(s) and/or principal investigator(s):
Roberto Amazonas, MD, Study Director, Affiliation: EMS

Summary

Recurrent genital herpes is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are effective oral prescription antiviral medicines available to reduce the discomfort of symptoms, such as famciclovir and aciclovir. This is a phase III, multicenter, randomized, parallel-group study to compare the efficacy and safety of treatment with famciclovir (125 mg) versus aciclovir (200 mg) in patients with active recurrent genital herpes.

Clinical Details

Official title: A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation

Secondary outcome: Safety Will be Evaluated by the Adverse Events Occurence

Detailed description: STUDY DESIGN

- Open-label, prospective, parallel group, intent to treat trial

- Experiment duration: 5 days

- 2 visits (days 1, and 5)

- Reduction of symptoms

- Adverse events evaluation

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion criteria: 1. Patients must be able to understand the study procedures agree to participate and give written consent. 2. Patients with clinical diagnosis of recurrent genital herpes; 3. Score symptoms higher than 4; 4. Negative pregnant urine test. Exclusion criteria: 1. Pregnancy or risk of pregnancy. 2. Lactation 3. Any pathology or past medical condition that can interfere with this protocol. 4. Non-steroidal anti-inflammatory drug , hormonal anti-inflammatory or immunosuppressive drugs (in the last 30 days and during the study); 5. Patients with immunodeficiency and/or immunosuppressive disease; 6. Hypersensitivity to components of the formula; 7. Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.

Locations and Contacts

Centro de Medicina Reprodutiva Dr Carlos Isaia Filho Ltda, Porto Alegre, RS, Brazil

Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

SPVita, Braganca Paulista, SP, Brazil

Caep Centro Avancado de Estudos E Pesquisas Ltda, Campinas, SP, Brazil

CEMICAMP - Centro de Pesquisas em Saúde Reprodutiva de Campinas, Campinas, SP, Brazil

CECIP - Centro de Estudos Clínicos do Interior Paulista, Jau, SP, Brazil

Hospital das Clínicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirao Preto, SP 14048900, Brazil

Afip - Associacao Fundo de Incentivo A Psicofarmacologia, Sao Paulo, SP, Brazil

Instituto Sirio Libanes de Ensino e Pesquisa, Sao Paulo, SP 01308-060, Brazil

Additional Information

Starting date: July 2012
Last updated: July 3, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017